PHILADELPHIA—Quality improvement (QI) tools in pediatric rheumatology can help overcome health outcome disparities that are based on race, gender identity, income and other factors, experts said in a session at ACR Convergence. With it well established that these disparities exist, it’s time to begin eliminating them, said Emily Smitherman, MD, MS, assistant professor of pediatric…
PHILADELPHIA—Officials from the U.S. Food & Drug Administration discussed recent drug approvals and drug safety issues at ACR Convergence in November in a session that captured the flurry of activity in the rheumatology sphere at the agency over the past year. Sabiha Khan, MD, clinical reviewer in the Division of Rheumatology and Transplant Medicine at…
PHILADELPHIA—The most vital component of avoiding drug shortages is early communication, officials from the U.S. Food & Drug Administration (FDA) said in a session at ACR Convergence 2022 in November. “Early notification is key in order to prevent and mitigate shortages,” said Hyun Son, PharmD, a member of the Drug Shortage Staff with the FDA…
When she saw vaping taking hold at a middle school, Kamala Nola, PharmD, MS, spoke up about concerns for the students’ risk of rheumatic disease and other health issues. At ACR Convergence 2022, Dr. Nola emphasized that every healthcare professional can act as an advocate through everyday actions.
PHILADELPHIA—Representatives of the Young Patients’ Autoimmune Research and Empowerment Alliance (YP AREA) led a panel titled Young Patients with Big Ideas Will Revolutionize Healthcare and Research, in which they discussed their work as advocates for adolescent and young adult (AYA) patients. YP AREA’s mission is to make autoimmune research more accessible and inclusive by involving…
PHILADELPHIA—Patients with rheumatic diseases often mount an adequate immune response after receiving COVID-19 vaccinations, but that is not always the case, and certain medications make patients more prone to having an insufficient response, said Judith James, MD, PhD, chair, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, at an ACR Convergence…
PHILADELPHIA—As rheumatologists, we care for patients who may or may not want to become pregnant. We aren’t obstetricians or gynecologists, but several of the drugs we prescribe for active rheumatic disease can negatively affect pregnancy outcomes. It’s imperative we understand how to effectively counsel our patients with rheumatic disease on the risks and benefits of…
PHILADELPHIA—It is often the case that a holistic approach to the management of autoimmune disease is what patients are looking for and may indeed provide optimal care for these patients. At ACR Convergence 2022, the session titled ACR Guideline for Physical, Psychosocial, Mind-Body and Nutritional Interventions for Rheumatoid Arthritis: An Integrative Approach to Treatment sought…
PHILADELPHIA—The term pseudogout has been a source of confusion among rheumatologists, especially as our understanding of calcium pyrophosphate crystal deposition (CPPD) disease has become more nuanced. This condition has many complex and interesting facets that warrant closer investigation. An ACR Convergence 2022 session sought to update the audience on the progress to date in developing…
PHILADELPHIA—Ever since the seminal work of C. Lockard Conley, MD, in 1952 of the discovery of the lupus anticoagulant, antiphospholipid syndrome (APS) has been of great interest to rheumatologists, hematologists and many others. At ACR Convergence 2022, the session titled Draft ACR/EULAR Antiphospholipid Syndrome Classification Criteria sought to summarize the rigorous process that went into…